Bayer Aktiengesellschaft (ETR:BAYN)
28.12
+0.77 (2.82%)
Aug 1, 2025, 5:38 PM CET
Smartsheet Revenue
Bayer Aktiengesellschaft had revenue of 13.74B EUR in the quarter ending March 31, 2025, a decrease of -0.20%. This brings the company's revenue in the last twelve months to 46.58B, down -0.92% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
46.58B
Revenue Growth
-0.92%
P/S Ratio
0.59
Revenue / Employee
512.50K
Employees
91,864
Market Cap
27.63B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.32B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.17B |
SCHOTT Pharma AG & Co. KGaA | 972.81M |
Bayer Aktiengesellschaft News
- 17 hours ago - Bayer gains after raising 2025 outlook - Seeking Alpha
- 1 day ago - Bayer Ups Guidance After Pharmaceuticals Unit Outperforms - The Wall Street Journal
- 1 day ago - Bayer increases Roundup litigation provisions by $1.37 billion - Reuters
- 1 day ago - Bayer Boosts 2025 Forecast, Sets US Legal Provisions - Wallstreet:Online
- 1 day ago - EQS-Adhoc: Bayer Aktiengesellschaft: Bayer upgrades currency-adjusted sales and earnings guidance for 2025 and establishes additional provisions for litigation in the United States - Wallstreet:Online
- 1 day ago - French court finds complaint brought by family in Bayer glyphosate case inadmissible, media says - Reuters
- 7 days ago - Bayer's Elinzanetant review period gets extended by FDA - Seeking Alpha
- 7 days ago - US FDA extends review of Bayer's menopause relief drug - Reuters